A new trading day began on Monday, with Ovid Therapeutics Inc (NASDAQ: OVID) stock price up 3.71% from the previous day of trading, before settling in for the closing price of $0.28. OVID’s price has ranged from $0.24 to $3.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -67.48%. With a float of $59.51 million, this company’s outstanding shares have now reached $71.11 million.
Let’s determine the extent of company efficiency that accounts for 23 employees. In terms of profitability, gross margin is 72.99%, operating margin of -10404.2%, and the pretax margin is -4557.12%.
Ovid Therapeutics Inc (OVID) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ovid Therapeutics Inc is 16.32%, while institutional ownership is 54.79%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -67.48% per share during the next fiscal year.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Here are Ovid Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.65 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Looking closely at Ovid Therapeutics Inc (NASDAQ: OVID), its last 5-days average volume was 1.3 million, which is a jump from its year-to-date volume of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 19.46%. Additionally, its Average True Range was 0.03.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 8.51%, which indicates a significant decrease from 25.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.24% in the past 14 days, which was lower than the 82.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2988, while its 200-day Moving Average is $0.7523. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $0.3057. Second resistance stands at $0.3207. The third major resistance level sits at $0.3361. If the price goes on to break the first support level at $0.2753, it is likely to go to the next support level at $0.2599. Now, if the price goes above the second support level, the third support stands at $0.2449.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
With a market capitalization of 20.66 million, the company has a total of 71,110K Shares Outstanding. Currently, annual sales are 570 K while annual income is -26,430 K. The company’s previous quarter sales were 130 K while its latest quarter income was -10,240 K.
